Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.

Enrico MaffiniLuisa GiacconeMoreno FestucciaLucia BrunelloIlaria BuondonnoDario FerreroMario BoccadoroChiara DellacasaAlessandro BuscaDomenico NoveroBenedetto Bruno

Published in: Journal of hematology & oncology (2016)

At 5 months from HSCT, the patient is well and in continuous hematological complete remission without flare of GvHD. Ruxolitinib was discontinued on day 156. Ruxolitinib is feasible and effective in SR-aGvHD though large prospective clinical trials are warranted.

Keyphrases

clinical trial
case report
hematopoietic stem cell
acute myeloid leukemia
open label
acute lymphoblastic leukemia